Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom in Danger of Being Demoted to Small-Cap Market

NEW YORK, Sept. 15 (GenomeWeb News) - Sequenom risks receiving a letter from the Nasdaq exchange warning the company of possible delisting if it fails to close above $1 by the end of the trading day on Sept. 17.

 

"There seems to be a threshold out there in the market place that is keeping us from closing above $1," said a Sequenom spokesperson. "We've hit above $1 a few times in the past week or so, but we haven't been able to close above $1."

 

The company also closed at $.99 on Sept. 14. The last time the company's stock closed above $1 was Aug. 5.

 

"Certainly we're making every effort to get the price above $1: increasing newsflow, meeting with the investment community to find some new buyers for stock, and fill some of the holes that have been created. That's the main plan, at the moment, to build demand for the stock," the spokesperson told GenomeWeb News.

 

If Sequenom fails to raise its share price above the $1 mark 90 days after receiving the letter, and maintain a closing price above the threshold for 10 trading days, it will be downgraded to the Nasdaq small-capitalization market. After that step, Sequenom would have to go through the same process, starting with closing above $1 in a 30-day period. Should it fail the second cycle, the company risks the delisting of its stock to the over-the-counter market.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more